WHO Issues Concern Over Severe Scarcity of Weight-Loss Jabs

Under a tenth of people who could benefit from GLP-1 drugs like Wegovy can access them, states the WHO as it issues its inaugural recommendations on the medications.

Given in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is advocating for more widespread and fairer availability to GLP-1 medication.

Per estimates, more than two billion will be obese by 2030 if no action is taken.

"The latest guidance recognises that excess weight is a chronic disease that can be managed with holistic and ongoing care," remarked its chief Tedros Adhanom Ghebreyesus.

High costs, constrained manufacturing, and distribution challenges are key hurdles to widespread availability to the injections that can help people shift substantial body mass, explains the body.

Skinny Jab Scarcity

Even under the current most optimistic scenario, the production of these medications could only cover about 100 million people – less than 10% of the global need, according to the WHO.

The advice urges nations and manufacturers to increase availability, by approaches including patent sharing.

Exclusive production rights on the active ingredient – the main component of Novo Nordisk's Wegovy – is due to expire in several countries in 2026.

The Way Weight-Loss Jabs Operate

The injections imitate a biological compound to slow digestion, reduce hunger and boost the sense of being full so people consume fewer calories.

Individuals commonly begin shedding pounds within a few weeks of beginning the once-weekly jabs.

Evidence points to people may put most of the weight back on a year later of stopping the treatment, as their usual appetite resume.

Being above a healthy weight raises your risk for contracting diseases, including diabetes, cardiovascular issues, stroke, and specific malignancies.

Obesity concerns individuals in countries worldwide and was associated with over three and a half million deaths worldwide in 2024, according to the health agency.